DekaBank Deutsche Girozentrale cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 0.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,379,620 shares of the biopharmaceutical company's stock after selling 18,753 shares during the period. DekaBank Deutsche Girozentrale owned about 0.13% of Pfizer worth $182,993,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. purchased a new position in Pfizer during the 1st quarter worth $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer during the 4th quarter worth $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Pfizer Price Performance
NYSE:PFE traded down $0.21 during mid-day trading on Wednesday, hitting $25.42. The company's stock had a trading volume of 16,534,988 shares, compared to its average volume of 41,701,904. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average of $23.80 and a 200-day moving average of $24.81. The company has a market capitalization of $144.49 billion, a price-to-earnings ratio of 18.42, a P/E/G ratio of 0.92 and a beta of 0.58.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.82 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.77%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.
Analyst Ratings Changes
Several research firms recently issued reports on PFE. UBS Group increased their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup increased their target price on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. TD Cowen cut their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average target price of $28.55.
Get Our Latest Stock Analysis on Pfizer
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
